Board Members

Dr Chris Nave

Chairman and Non-Executive Director


Chris Nave has been a director since January 2011. He is a founding partner of Brandon Capital Partners and Principal Executive of the Medical Research Commercialisation Fund.  Chris has been directly in the management, fundraising, and successful spinouts of various companies in the life sciences industry. He previously was Director of Commercialisation at the Baker IDI Heart and Diabetes Institute, Melbourne, Australia, and prior to this, was Manager of the Biotechnology Team at Melbourne Ventures.  Chris has international experience with Leiras Pharmaceuticals in Finland, a wholly owned subsidiary of Schering AG, working for their Business Development group. He successfully moved companies to the US, securing investment from US investors for these companies. Chris is currently a Director of Osprey Medical Inc., Spinifex Pharmaceuticals, Fibrotech Therapeutics, Fluorotrop Pty Ltd and BACE Therapeutics. Chris has a first-class Honours degree in Science and a Ph.D. in Endocrinology and Physiology from the University of Melbourne.

Dr James Williams


BSc(Hons) PhD MBA

James has been a Director of PolyActiva since January 2013.  He is a Founder and Investment Director of Yuuwa Capital LP, a venture capital firm based in Western Australia. Prior to establishing Yuuwa Capital, James was Managing Director of two medical device companies, ASX-listed Resonance Health Ltd and Argus Biomedical Pty Ltd, both of which took their products to market under his guidance, and CEO of drug discovery company Dimerix Bioscience Pty Ltd.  He also co-founded and is a former CSO and Director of iCeutica, Inc., a clinical stage nano drug reformulation company that was acquired in 2011. James is a Director of Yuuwa investee companies Adalta Pty Ltd and Gordiantec Pty Ltd.  He is also a Director of Linear Clinical Research Ltd, a specialist early phase clinical trial unit, a member of the “Panel of Experts” for the University of Western Australia’s Pathfinder Fund and remains a Director of Dimerix Bioscience. He completed his undergraduate degree in Biochemistry at the University of Aberdeen, PhD at Melbourne University and MBA at the University of Western Australia.

Professor Barrie Finnin

Non-Executive Director

BPharm PhD PhC

Barrie has been a director since 1999 and is a co-inventor of Acrux’s technology. He is currently an adjunct Professor in the Faculty of Pharmacy and Pharmaceutical Sciences at the Victorian College of Pharmacy, Monash University, Australia. Barrie has more than 15 years’ experience in the management of commercially funded research in an academic setting. He has conducted projects at various phases of drug development and manufacture for major pharmaceutical companies, and has experience in the design and commissioning of GMP manufacturing. He also has experience as an external evaluator of new drug applications for the Australian Therapeutic Goods Administration (TGA).

Tracy Valorie

Non-Executive Director


Tracy Valorie joined the board of PolyActiva in 2020.  She is the owner of TMV Associates LLC a strategic consulting business, has almost 30 years of experience in the pharmaceutical and biotech industry.  Most recently Ms. Valorie served as the Sr. Vice President, General Manager of the US Pharmaceutical and Surgical Businesses at Bausch + Lomb.   Prior to joining B+L in 2012, Ms Valorie was Pfizer’s Commercial Lead of Ophthalmology where she had Global responsibility for the Ophthalmology Brands as well as responsibility for commercial development of the mid-stage portfolio and long-range strategic planning. Her 30 year career in the industry has included roles in discovery science, clinical development, early commercial assessment, marketing and strategic planning. Ms. Valorie is a past board member of OWL, Ophthalmic World Leaders, and now sits on their recently formed advisory board. OWL’s vision is to promote and develop diverse leadership to advance Ophthalmic Innovation and Patient Care. She and has previously held board membership seats at The Glaucoma Foundation and the ARVO Foundation for Eye Research. Tracy holds a Masters in Business Administration from Rensselaer Polytechnic Institute and a Bachelor of Science in Molecular Biology from the University of Connecticut at Storrs, CT, USA.

Dr Russell Tait

Chief Executive Officer

BPharm PhD MBA

Russell has been CEO since February 2010, and joined the board of PolyActiva in August 2011.  He is a co-inventor of PolyActiva’s technology.  He is currently an adjunct Associate Lecturer at Monash University in the Faculty of Pharmacy and Pharmaceutical Sciences at the Victorian College of Pharmacy, Australia. Russell has more than 20 years’ experience in drug delivery and pharmaceutical product development with leading pharmaceutical companies, including Glaxo Australia, Faulding (now Hospira) and CSIRO.  Whilst at CSIRO, he was the recipient of the CSIRO medal for Business Excellence for having lead the team responsible for publishing the CSIRO Total Well Being Diet book.  He was appointed Chief Executive Officer of PolyActiva Pty Ltd in February 2010.  Russell holds degrees in Pharmacy from the Victorian College of Pharmacy, University of Melbourne and is a registered pharmacist. He also took a post-doc position at Kansas University.